QHSLab Inc., a medical device and digital health company, completed the repurchase and retirement of its outstanding legacy convertible debt.
The repurchase strengthened the company's balance sheet, reduced future dilution risk, and eliminated a significant overhang on the common stock.
In Q3 2025, QHSLab reported robust year-over-year revenue growth, expanded gross profit, and improved operating metrics.
Legacy Debt Repurchase
QHSLab retired and canceled over $1.4 million of outstanding principal, accrued default interest, and potential fees associated with legacy convertible notes.
Financial Highlights - Q3 2025
Revenue increased by 35% to $737,066, gross profit increased by 35% to $493,631, and operating income was $96,251.
Digital Medicine Expansion
QHSLab continued deploying its ISP platform, driving recurring SaaS and service revenue.
- The repurchase of legacy debt significantly improved QHSLab's financial position and reduced potential dilution risks for shareholders.
- QHSLab's strong Q3 2025 financial results indicate operational momentum and growth in digital health services.
- Eliminating defaulted debt obligations enhances the company's financial trajectory and supports future growth and innovation.
QHSLab's strategic move to repurchase legacy debt demonstrates financial discipline and positions the company for sustainable growth in digital health services. The strong Q3 2025 results underscore the effectiveness of QHSLab's technology and market strategy, signaling a promising path for future profitability and shareholder value.